Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Balslev

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
NPJ Breast Cancer|March 7, 2020
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patientsMaj-Britt Jensen, Anne-Vibeke Lænkholm, Eva Balslev, et al.
Cancers|July 2, 2021
Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast CancersJeppe Thagaard, Elisabeth Specht Stovgaard, Line Grove Vognsen, et al.
International Journal of Cancer|November 10, 2018
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trialKarama Asleh, Stina Lyck Carstensen, Charlotte L Tykjaer Jørgensen, et al.
Acta Oncologica (Stockholm, Sweden)|December 6, 2017
An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG)Anne-Vibeke Laenkholm, Dorthe Grabau, Maj-Lis Møller Talman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2017
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized TrialBent Ejlertsen, Malgorzata K Tuxen, Erik Hugger Jakobsen, et al.
Breast Cancer (Tokyo, Japan)|October 27, 2019
Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assayTroels Dreier Christensen, Anna Sofie Kappel Buhl, Ib Jarle Christensen, et al.
Breast Cancer Research and Treatment|August 13, 2018
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded studyAnna Sofie Kappel Buhl, Troels Dreier Christensen, Ib Jarle Christensen, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2016
Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centersAdam Gondos, Lina Jansen, Jörg Heil, et al.
Breast Cancer Research and Treatment|August 1, 2020
Prognostic value of histopathological DCIS features in a large-scale international interrater reliability studyEmma J Groen, Jan Hudecek, Lennart Mulder, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
NPJ Breast Cancer|March 7, 2020
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patientsMaj-Britt Jensen, Anne-Vibeke Lænkholm, Eva Balslev, et al.
Cancers|July 2, 2021
Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast CancersJeppe Thagaard, Elisabeth Specht Stovgaard, Line Grove Vognsen, et al.
International Journal of Cancer|November 10, 2018
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trialKarama Asleh, Stina Lyck Carstensen, Charlotte L Tykjaer Jørgensen, et al.
Acta Oncologica (Stockholm, Sweden)|December 6, 2017
An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG)Anne-Vibeke Laenkholm, Dorthe Grabau, Maj-Lis Møller Talman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2017
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized TrialBent Ejlertsen, Malgorzata K Tuxen, Erik Hugger Jakobsen, et al.
Breast Cancer (Tokyo, Japan)|October 27, 2019
Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assayTroels Dreier Christensen, Anna Sofie Kappel Buhl, Ib Jarle Christensen, et al.
Breast Cancer Research and Treatment|August 13, 2018
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded studyAnna Sofie Kappel Buhl, Troels Dreier Christensen, Ib Jarle Christensen, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2016
Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centersAdam Gondos, Lina Jansen, Jörg Heil, et al.
Breast Cancer Research and Treatment|August 1, 2020
Prognostic value of histopathological DCIS features in a large-scale international interrater reliability studyEmma J Groen, Jan Hudecek, Lennart Mulder, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
Pageof 9